EP1185265A4 - Il-8 rezeptorantagonisten - Google Patents

Il-8 rezeptorantagonisten

Info

Publication number
EP1185265A4
EP1185265A4 EP00941455A EP00941455A EP1185265A4 EP 1185265 A4 EP1185265 A4 EP 1185265A4 EP 00941455 A EP00941455 A EP 00941455A EP 00941455 A EP00941455 A EP 00941455A EP 1185265 A4 EP1185265 A4 EP 1185265A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00941455A
Other languages
English (en)
French (fr)
Other versions
EP1185265A1 (de
Inventor
Gregory M Benson
Melvin Clarence Rutledge
Katherine L Widdowson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1185265A1 publication Critical patent/EP1185265A1/de
Publication of EP1185265A4 publication Critical patent/EP1185265A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP00941455A 1999-06-16 2000-06-15 Il-8 rezeptorantagonisten Withdrawn EP1185265A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14002499P 1999-06-16 1999-06-16
US140024P 1999-06-16
PCT/US2000/016506 WO2000076501A1 (en) 1999-06-16 2000-06-15 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
EP1185265A1 EP1185265A1 (de) 2002-03-13
EP1185265A4 true EP1185265A4 (de) 2004-02-04

Family

ID=22489379

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00941455A Withdrawn EP1185265A4 (de) 1999-06-16 2000-06-15 Il-8 rezeptorantagonisten

Country Status (19)

Country Link
EP (1) EP1185265A4 (de)
JP (1) JP2003501463A (de)
KR (1) KR20020015347A (de)
CN (1) CN1356899A (de)
AR (1) AR024350A1 (de)
AU (1) AU766235B2 (de)
BR (1) BR0011122A (de)
CA (1) CA2377386A1 (de)
CO (1) CO5190696A1 (de)
CZ (1) CZ20014472A3 (de)
HU (1) HUP0201582A3 (de)
IL (1) IL145762A0 (de)
MX (1) MXPA01013005A (de)
NO (1) NO20016052L (de)
NZ (1) NZ514696A (de)
PL (1) PL352213A1 (de)
TR (1) TR200103638T2 (de)
WO (1) WO2000076501A1 (de)
ZA (1) ZA200109480B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139601A (en) 2002-10-09 2009-10-30 Schering Corp Thiadiazoledioxides and thiadiazoleoxides as cxc-and cc-chemokine receptor ligands
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10334309A1 (de) * 2003-07-28 2005-03-03 Aventis Pharma Deutschland Gmbh Substituierte Thiazol-Benzoisothiazoldioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
AU2004268949A1 (en) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl C-kit inhibitors
EP1664032B1 (de) 2003-08-21 2008-11-05 OSI Pharmaceuticals, Inc. N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitoren
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
MXPA06007076A (es) 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
WO2006047302A1 (en) 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
EP1831206B1 (de) 2004-12-01 2011-08-24 OSI Pharmaceuticals, Inc. N-substituierte benzimidazolyl-c-kit-inhibitoren und kombinatorische benzimidazolbibliothek
CN102066372B (zh) 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 含脲基的5，6元杂芳双环化合物作为激酶抑制剂
EP2377850A1 (de) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1-Vanilloidrezeptorantagonisten mit einem bizyklischen Teil
CN102060780B (zh) 2010-12-27 2014-11-05 雅本化学股份有限公司 2-(n-取代)-氨基苯并咪唑衍生物的制备方法
CN111116502A (zh) * 2018-10-30 2020-05-08 中国石油化工股份有限公司 一步法合成苯骈三氮唑的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032439A1 (en) * 1997-01-23 1998-07-30 Smithkline Beecham Corporation Il-8 receptor antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032439A1 (en) * 1997-01-23 1998-07-30 Smithkline Beecham Corporation Il-8 receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOWARD O M Z ET AL: "CHEMOKINES: PROGRESS TOWARD IDENTIFYING MOLECULAR TARGETS FOR THERAPEUTIC AGENTS", TRENDS IN BIOTECHNOLOGY, ELSEVIER, AMSTERDAM,, GB, vol. 14, February 1996 (1996-02-01), pages 46 - 51, XP002919059, ISSN: 0167-7799 *
See also references of WO0076501A1 *

Also Published As

Publication number Publication date
NO20016052D0 (no) 2001-12-11
ZA200109480B (en) 2002-11-18
CN1356899A (zh) 2002-07-03
CA2377386A1 (en) 2000-12-21
PL352213A1 (en) 2003-08-11
IL145762A0 (en) 2002-07-25
AR024350A1 (es) 2002-10-02
BR0011122A (pt) 2002-02-26
WO2000076501A1 (en) 2000-12-21
CO5190696A1 (es) 2002-08-29
KR20020015347A (ko) 2002-02-27
TR200103638T2 (tr) 2002-04-22
EP1185265A1 (de) 2002-03-13
AU766235B2 (en) 2003-10-09
JP2003501463A (ja) 2003-01-14
CZ20014472A3 (cs) 2002-06-12
AU5616100A (en) 2001-01-02
MXPA01013005A (es) 2002-07-02
NZ514696A (en) 2004-03-26
HUP0201582A2 (hu) 2002-12-28
NO20016052L (no) 2001-12-11
HUP0201582A3 (en) 2003-02-28

Similar Documents

Publication Publication Date Title
EP1284956A4 (de) Il-8 receptor antagonisten
PL352232A1 (en) Il-8 receptor antagonists
IL151429A0 (en) Il-8 receptor antagonists
AU4560601A (en) Il-8 receptor antagonists
IL145762A0 (en) Il-8 receptor antagonists
PL351946A1 (en) Il-8 receptor antagonists
EP1274415A4 (de) Il-8 rezeptorantagonisten
IL151210A0 (en) Il-8 receptor antagonists
EP1265905A4 (de) Il-2 receptor antagonisten
HUP0201302A3 (en) Il-8 receptor antagonists
EP1274413A4 (de) Il-8 rezeptorantagonisten
EP1274428A4 (de) Il-8-rezeptorantagonisten
EP1047424A4 (de) Il-8 rezeptor antagonisten
EP1039903A4 (de) Il-8 rezeptor antagonisten
EP1194143A4 (de) Il-8 rezeptor-antagonisten
EP1261329A4 (de) Il-8-rezeptor-antagonisten
EP1185270A4 (de) Interleukin-8 rezeptor-antogonisten
IL146515A0 (en) Il-8 receptor antagonists
IL146214A0 (en) Il-8 receptor antagonists
PL346178A1 (en) Il-8 receptor antagonists
EP1265603A4 (de) Il-9 receptor-antagonisten
EP1237548A4 (de) Il-8 rezeptor antagonisten
ZA985975B (en) IL-8 receptor antagonists
ZA985813B (en) IL-8 receptor antagonists
EP1087661A4 (de) Il-8 rezeptor antagonisten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20011108

A4 Supplementary search report drawn up and despatched

Effective date: 20031229

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/4184 A

Ipc: 7A 61K 31/4192 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040309

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044474

Country of ref document: HK